Last updated: 2026-09-22 00:30:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Amylyx Pharmaceuticals, Inc. (AMLX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $32.42, with a market capitalisation of $4.14B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.83 to $41.14. This page covers its latest market performance, valuation, price trends and company information.
$4.14B | |
$32.55 | |
$41.93 | |
$1.58 | |
$32.41 | |
812.06K | |
2.48M | |
-- | |
$41.14 | |
$10.83 | |
-- | |
-- |
Amylyx Pharmaceuticals, Inc. (AMLX) last closed at $32.41 as of 2026-09-21 23:31:00, unchanged from the previous close of $32.41.
During the latest regular trading session, AMLX traded between $1.58 and $41.93, with a volume of 812.06K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Amylyx Pharmaceuticals, Inc. (AMLX) moved from $32.09 to $32.42, representing a gain of 1.04% ($0.33).
The stock traded between $31.37 and $34.35 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1.75 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 71.2%
AMLX is currently trading at $32.42, placing it 71.2% of the way from its 52-week low of $10.83 to its 52-week high of $41.14. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 136 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Amylyx Pharmaceuticals, Inc. (AMLX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.